ArticleAmerican journal of preventive medicine2018
Racial and Geographic Disparities in Hepatocellular Carcinoma Outcomes.
Article in American journal of preventive medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Pooled it
- FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Racial and ethnic survival disparities in primary liver cancer in the United States: a National Cancer Database propensity score-matched study.Hepatic oncology · 2026Article
- Assessment of Differences in Colorectal Cancer Outcomes by Geographic Region for Black Patients in the United States.Journal of racial and ethnic health disparities · 2026Article
- Oncologic outcomes after declining lung cancer surgery: mixed methods analysis of a prospective pilot cohort.Journal of thoracic disease · 2026Article
- Disparities in Diagnosis, Management, and Outcomes of Hepatocellular Carcinoma: A Review of Global and Sociodemographic Factors.Journal of gastrointestinal cancer · 2026Review
- International perspectives on LI-RADS.Abdominal radiology (New York) · 2025Review
- Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.Annals of surgical oncology · 2025Article
- Hepatocellular carcinoma national burden across different geographical regions in the United States between 2001 and 2020.World journal of methodology · 2024Article
- Community-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Observational
- Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes.Cancer reports (Hoboken, N.J.) · 2023Review
- Ethnic disparities in the epidemiology, treatment, and outcome of patients with hepatocellular carcinoma in the United States.Hepatoma research · 2023Article
- Understanding the Changing Landscape of Health Disparities in Chronic Liver Diseases and Liver Cancer.Gastro hep advances · 2023Article
- The Effect of Race on Outcomes in Veterans With Hepatocellular Carcinoma at a Single Center.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2022Article
- Understanding gastrointestinal cancer mortality disparities in a racially and geographically diverse population.Cancer epidemiology · 2022Article
- Emissions of dioxins and dioxin-like compounds and incidence of hepatocellular carcinoma in the United States.Environmental research · 2022Article
- Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts.Advances in cancer research · 2022Article
- Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact.Hepatology communications · 2022Article
- The role of racial segregation in treatment and outcomes among patients with hepatocellular carcinoma.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2021Article
- Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
introductionHepatocellular carcinoma disproportionately affects minorities. Southern states have high proportions of black populations and prevalence of known risk factors. Further research is needed to understand the role of southern geography in hepatocellular carcinoma disparities. This paper examined racial disparities in hepatocellular carcinoma incidence, demographics, tumor characteristics, receipt of treatment, and all-cause mortality in southern and non-southern cancer registries.
methodsSurveillance Epidemiology and End Results data were probed in 2015 to identify 43,868 patients diagnosed with hepatocellular carcinoma from 2000 to 2012 (5,455 in southern registries [Atlanta, Louisiana, and Rural and Greater Georgia]).
resultsSouthern registries showed steeper increases of age-adjusted hepatocellular carcinoma incidence (from 2.89 to 5.29cases/100,000 people) versus non-southern areas (from 3.58 to 5.54cases/100,000 people). Blacks were over-concentrated in southern registries (32% vs 10%). Compared with whites, blacks were significantly younger at diagnosis, more likely diagnosed with metastasis, and less likely to receive surgical therapies in both registry groups. After adjustment, blacks had a significantly higher risk of all-cause mortality compared with whites in southern (hazard ratio=1.10, p=0.007) and non-southern areas (hazard ratio=1.08, p<0.001). For overall populations, southern registries had higher risk of all-cause mortality versus non-southern registries (hazard ratio=1.13, p<0.001).
conclusionsAge-adjusted incidence rates of hepatocellular carcinoma are plateauing overall, but are still rising in southern areas. Race and geography had independent associations with all-cause mortality excess risk among patients with hepatocellular carcinoma. Further studies are needed to understand the root causes of potential mortality risk excess among overall populations with hepatocellular carcinoma living in the South. SUPPLEMENT INFORMATION: This article is part of a supplement entitled African American Men's Health: Research, Practice, and Policy Implications, which is sponsored by the National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.